Elliot Favus - Anavex Life Director
| AVXL Stock | USD 3.41 0.27 7.34% |
Director
Dr. Elliot J. Favus, M.D. is an Independent Director of Anavex Life Sciences Corporationration Elliot Favus is Chief Executive Officer of Favus Institutional Research, a healthcare research firm serving institutional investors. He was a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and subsequently at OchZiff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at Mount Sinai School of Medicine in New York. He attended the University of Michigan the University of Chicago Pritzker School of Medicine and the NYUBellevue Hospital Internal Medicine Residency Program . He is boardcertified in Internal Medicine and has 10 years of basic science laboratory experience working on human genetics projects at Harvard Medical School, the University of Chicago and the University of Pittsburgh. since 2014.
| Age | 41 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 630 5th Avenue, New York, NY, United States, 10111 |
| Phone | 844 689 3939 |
| Web | https://www.anavex.com |
Anavex Life Management Efficiency
The company has return on total asset (ROA) of (0.207) % which means that it has lost $0.207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3188) %, meaning that it created substantial loss on money invested by shareholders. Anavex Life's management efficiency ratios could be used to measure how well Anavex Life manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.29. Return On Capital Employed is expected to rise to -0.37 this year. At this time, Anavex Life's Total Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 186.4 M this year, although the value of Other Assets will most likely fall to about 3.7 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| DeLyle Bloomquist | PDS Biotechnology Corp | 59 | |
| Peter Hug | ADC Therapeutics SA | 62 | |
| Ian Clark | Corvus Pharmaceuticals | 57 | |
| Richard Jones | Mereo BioPharma Group | 50 | |
| Thomas Pfisterer | ADC Therapeutics SA | 39 | |
| Gary Bridger | X4 Pharmaceuticals | N/A | |
| Lawrence Alleva | Adaptimmune Therapeutics Plc | 68 | |
| Scott Morrison | Corvus Pharmaceuticals | 60 | |
| James Loughlin | PDS Biotechnology Corp | 75 | |
| Allison JeynesEllis | Agenus Inc | 52 | |
| Linda Grais | Corvus Pharmaceuticals | 61 | |
| Charles Sigal | Adaptimmune Therapeutics Plc | 65 | |
| Elisha Gould | Corvus Pharmaceuticals | 60 | |
| Peter Moldt | Corvus Pharmaceuticals | 57 | |
| Elliot Sigal | Adaptimmune Therapeutics Plc | 65 | |
| Peter Thompson | Adaptimmune Therapeutics Plc | 55 | |
| Gregory Freitag | PDS Biotechnology Corp | 56 | |
| Kunal Kashyap | Mereo BioPharma Group | 52 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| John Furey | Adaptimmune Therapeutics Plc | 53 | |
| Steve Krognes | Corvus Pharmaceuticals | 49 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.21 |
Anavex Life Sciences Leadership Team
Elected by the shareholders, the Anavex Life's board of directors comprises two types of representatives: Anavex Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anavex. The board's role is to monitor Anavex Life's management team and ensure that shareholders' interests are well served. Anavex Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anavex Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elliot Favus, Director | ||
| CPA CPA, Principal Treasurer | ||
| Christopher Missling, President CEO, CFO, Treasurer, Secretary, Director | ||
| David RPh, Senior Affairs | ||
| Sandra Boenisch, Principal Financial Officer | ||
| Stephan Toutain, Senior Vice President - Operations | ||
| Dr RPh, VP Affairs | ||
| Kun Jin, Head Biostatistics | ||
| MD MPH, Chief Officer | ||
| Athanasios Skarpelos, Director | ||
| Walter MD, Chief Officer | ||
| Walter Kaufmann, Chief Medical Officer | ||
| MS MBA, Senior COO | ||
| Adebayo Laniyonu, Senior Development | ||
| Bernd Metzner, Director | ||
| Steffen Thomas, Director | ||
| Peter Donhauser, Director | ||
| CGA CPA, Principal Treasurer | ||
| Clint Tomlinson, VP Corporate | ||
| Claus Velden, Director | ||
| MBA MS, President, Chairman |
Anavex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anavex Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 158.41 M | ||||
| Shares Outstanding | 82.11 M | ||||
| Shares Owned By Insiders | 3.14 % | ||||
| Shares Owned By Institutions | 32.14 % | ||||
| Number Of Shares Shorted | 22.12 M | ||||
| Price To Earning | (11.03) X | ||||
| Price To Book | 2.60 X | ||||
| EBITDA | (47.5 M) |
Anavex Life Implied Volatility | 0.0 |
Anavex Life's implied volatility exposes the market's sentiment of Anavex Life Sciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Anavex Life's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Anavex Life stock will not fluctuate a lot when Anavex Life's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Anavex Life in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Anavex Life's short interest history, or implied volatility extrapolated from Anavex Life options trading.
Pair Trading with Anavex Life
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anavex Life position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anavex Life will appreciate offsetting losses from the drop in the long position's value.Moving against Anavex Stock
| 0.75 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
| 0.75 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.71 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.7 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.68 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Anavex Life could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anavex Life when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anavex Life - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anavex Life Sciences to buy it.
The correlation of Anavex Life is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anavex Life moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anavex Life Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anavex Life can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Anavex Stock analysis
When running Anavex Life's price analysis, check to measure Anavex Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anavex Life is operating at the current time. Most of Anavex Life's value examination focuses on studying past and present price action to predict the probability of Anavex Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anavex Life's price. Additionally, you may evaluate how the addition of Anavex Life to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Anavex Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Return On Assets (0.21) | Return On Equity (0.32) |
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.